

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A05/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B44, B51; Cw5, Cw15; DR4, DR11; DQ7, -

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested	18	18	18	18	13	14	14	14			
Positive	1	17	0	18	4	13	1	13			
Negative	17	1	18	0	9	1	13	1			
NT/Equivocal	1	1	1	1	3	2	2	2			
% Positive	5.6%	94.4%	0.0%	100.0%	30.8%	92.9%	7.1%	92.9%			
% Negative	94.4%	5.6%	100.0%	0.0%	69.2%	7.1%	92.9%	7.1%			
Consensus	Negative	Positive	Negative	Positive	Not Assessed	Positive	Negative	Positive			
HLA Antibody Specificity (Defined By CDC)	B40, B13, B47	B12, DQ1	DR7	A2, A28, A9	B40, B13, B47	B12, DQ1	DR7	A2, A28, A9			
			Without DTT				Without DTT				
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
101	YES	YES	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	
114	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	Delayed delivery
116	YES	YES	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
117	YES	NO	Negative	Positive	Negative	Positive					
133	YES	YES	Negative	Positive	Negative	Positive	NT	NT	NT	NT	Cell viability too low
136	YES	NO	Negative	Negative	Negative	Positive					
145	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Positive	Positive	
149	YES	NO	Negative	Positive	Negative	Positive					
162	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
163	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
186	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
204	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
206	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
212	YES	YES	Negative	Positive	Negative	Weak Positive	Negative	Positive	Negative	Negative	
227	YES	YES	Negative	Positive	Negative	Positive	NT	Positive	Negative	Positive	Technical failure
268	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
284	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
311	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
315	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A05/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101	1	6	1	6	1	1	1	6		100	100
114	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
116	6	8	1	8	4	8	1	8		98	95
117	1	8	1	8					92		
133	0	8	0	8	NT	NT	NT	NT		90	20
136	2	2	1	8						90	
145		6-8		8		8	6-8	8		100	100
149		4-6		6-8					70		
162		8		8	6	8		8		100	100
163	1	8	1	8	1	8	1	8		98	98
186	0	8	0	8	2	8	0	8		99	99
204	2	8	1	6	2	8	2	8		90	85
206	1	8	1	8	6	8	1	8		90	90
212									99	97	98
227		8		8		8		8	90	90	90
268	1	8	1	8	1	8	1	6		98	98
284	1	8	1	8	1	8	1	8		99	95
311	1	8	1	6	1	8	1	8		100	100
315	1	8	1	6	1	8	1	8	80	80	80

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A05/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

Lab No.	Summary of Results															
	PBL				PBL Without DTT				T-Cells				T-Cells Without DTT			
	Without DTT				Serum 1	Serum 2	Serum 3	Serum 4	Without DTT				Serum 1	Serum 2	Serum 3	Serum 4
	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength
162	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Positive		8		8
268									Negative	Positive	Negative	Positive	1	8	1	8
284									Negative	Positive	Negative	Positive	1	8	1	8

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A05/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B44, B51; Cw5, Cw15; DR4, DR11; DQ7, -

	Summary of Results							
	PBL/T-Cells				B-Cells			
Total tested	14	14	14	14	12	13	13	13
Positive	1	12	0	13	4	11	0	12
Negative	13	2	14	1	8	2	13	1
NT/Equivocal	2	2	2	2	3	2	2	2
% Positive	7.1%	85.7%	0.0%	92.9%	33.3%	84.6%	0.0%	92.3%
% Negative	92.9%	14.3%	100.0%	7.1%	66.7%	15.4%	100.0%	7.7%
Consensus	Negative	Positive	Negative	Positive	Not Assessed	Positive	Negative	Positive
HLA Antibody Specificity (Defined By CDC)	B40, B13, B47	B12, DQ1	DR7	A2, A28, A9	B40, B13, B47	B12, DQ1	DR7	A2, A28, A9

Lab No.	PBL/T Cell Assessment	B Cell Assessment	With DTT				With DTT				Comments
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
101	YES	YES	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Delayed delivery
114	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	
116	YES	YES	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Cell viability too low
133	YES	YES	Negative	Positive	Negative	Positive	NT	NT	NT	NT	
149	YES	NO	NT	Equivocal	NT	Equivocal					
162	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Technical failure
163	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
186	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
204	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
206	YES	YES	Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
212	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
227	YES	YES	Negative	Positive	Negative	Positive	NT	Positive	Negative	Positive	
268	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
284	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
311	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
315	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A05/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101	1	1	1	4	1	1	1	8		100	100
114	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
116	6	8	1	8	6	8	1	8		98	95
133	0	8	0	8	NT	NT	NT	NT		90	20
149									70		
162		8		8	4/6	8		8		100	100
163	1	8	1	8	1	8	1	8		98	98
186	0	8	0	6	2	8	0	6		99	99
204	2	8	1	6	2	8	2	8		90	85
206	1	8	1	8	6	8	1	8		90	90
212									99	97	98
227		8		8		8		8	90	90	90
268	1	8	1	8	1	8	1	6		98	98
284	1	8	1	8	2	8	1	8		99	95
311	1	8	1	6	1	8	1	8		100	100
315	1	8	1	6	1	8	1	8	80	80	80

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A05/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

Lab No.	Summary of Results															
	PBL				PBL With DTT				T-Cells				T-Cells With DTT			
	With DTT				Serum 1	Serum 2	Serum 3	Serum 4	With DTT				Serum 1	Serum 2	Serum 3	Serum 4
	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength
162	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Positive	Negative	Positive		8		8
268									Negative	Positive	Negative	Positive	1	8	1	8
284									Negative	Positive	Negative	Positive	1	8	1	8